ES2688447T3 - Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales - Google Patents

Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales Download PDF

Info

Publication number
ES2688447T3
ES2688447T3 ES10822363.7T ES10822363T ES2688447T3 ES 2688447 T3 ES2688447 T3 ES 2688447T3 ES 10822363 T ES10822363 T ES 10822363T ES 2688447 T3 ES2688447 T3 ES 2688447T3
Authority
ES
Spain
Prior art keywords
muscular atrophy
animals
methods
prevent
treat sarcopenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10822363.7T
Other languages
English (en)
Inventor
Yuanlong Pan
Sunil Kochhar
Serge André Dominique REZZI
Françoise-Pierre MARTIN
Emma Pere-Trepat
Sebastiano Collino
Francia Arce Vera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2688447T3 publication Critical patent/ES2688447T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Abstract

Una composición que contiene una o más isoflavonas obtenidas de la soja para usar en la prevención o en el tratamiento de la atrofia muscular o la sarcopenia en un perro, seleccionando las isoflavonas del grupo constituido por daidzeína, daidzina, gliciteína, equol, genisteína y glicitina.

Description

imagen1
imagen2
imagen3
imagen4
Tabla 1
Metabolitos en el plasma sanguíneo que describen los cambios con el tiempo en perros tratados y de control
Metabolitos más altos (H)/ más bajos (L) con el tiempo respecto a la línea base
Tiempo 3 frente a 0 Tiempo 6 frente a 0 Tiempo 9 frente a 0
Grupos
C Iso C Iso C Iso
Espectros CPMG descriptores del modelo
R2X = 0,20; R2Y = 0,97; Q2Y = 0,32 R2X = 0,30; R2Y = 0,92; Q2Y = 0,44 R2X = 0,23; R2Y = 0,97; Q2Y = 0,33 R2X = 0,27; R2Y = 0,91; Q2Y = 0,31 R2X = 0,25; R2Y = 0,97; Q2Y = 0,63 R2X = 0,31; R2Y = 0,92; Q2Y = 0,12
3-D-Hidroxibutirato
L (p = 0,0228) L (p = 0,0301)
3-Metil-histidina
H (p = 0,0058) H (p = 0,0206)
Colina
L (p = 0,0318)
Glutamato
L (p = 0,0065) L (p = 0,0036) L (p = 0,0022)
Histidina
H (p = 0,0054) L (p = 0,0426) H (p = 0,0042)
Leucina
L (p = 0,0151) H (p = 0,0164) L (p = 0,0317)
Metionina
H (p = 0,0602)
Señal metilo de ácidos grasos
L (p = 0,0041) L (p = 0,0000) L (p = 0,0005) L (p = 0,0000) L (p = 0,0025) L (p = 0,0001)
Treonina
H (p = 0,0050) L (p = 0,0247) H (p = 0,0002) L (p = 0,0002) H (p = 0,0253)
Valina
H (p = 0,0039) L (p = 0,0097) H (p = 0,0103)
Espectros de difusión descriptores del modelo
R2X = 0,46; R2Y = 0,81; Q2Y = 0,18 Q2Y < 0 * R2X = 0,48; R2Y = 0,81; Q2Y = 0,33 Q2Y < 0 * R2X = 0,51; R2Y = 0,89; Q2Y = 0,61 Q2Y < 0 *
Señal metilo de ácidos grasos
L (p = 0,1304) L (p = 0,0148) L (p = 0,0030)
Proteínas
L (p = 0,0104) L (p = 0,0011)
Lipoproteína de muy baja densidad (VLDL)
H (p = 0,0070) H (p = 0,0047)
En la exposición se han descritos formas de ejecución preferidas típicas de la presente invención. A pesar del empleo de términos específicos, éstos se usan solo en un sentido genérico y descriptivo y no con fines limitativos. El
5 alcance de la presente invención se establece en las reivindicaciones. Obviamente caben muchas modificaciones y variaciones de la presente invención a la luz de las revelaciones anteriores. Por tanto debe entenderse que dentro del alcance de las reivindicaciones adjuntas, la invención puede ponerse en práctica de otra forma que la descrita específicamente.
10
6

Claims (1)

  1. imagen1
ES10822363.7T 2009-10-09 2010-10-08 Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales Active ES2688447T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27863309P 2009-10-09 2009-10-09
US278633P 2009-10-09
PCT/US2010/002722 WO2011043827A1 (en) 2009-10-09 2010-10-08 Methods for preventing or treating sarcopenia and muscle atrophy in animals

Publications (1)

Publication Number Publication Date
ES2688447T3 true ES2688447T3 (es) 2018-11-02

Family

ID=43857050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10822363.7T Active ES2688447T3 (es) 2009-10-09 2010-10-08 Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales

Country Status (12)

Country Link
US (1) US9301941B2 (es)
EP (1) EP2485740B1 (es)
JP (1) JP6122638B2 (es)
CN (1) CN102573857A (es)
AU (1) AU2010303872B2 (es)
BR (1) BR112012008238A2 (es)
CA (1) CA2776950C (es)
ES (1) ES2688447T3 (es)
IN (1) IN2012DN02624A (es)
MX (1) MX2012004118A (es)
RU (1) RU2558534C2 (es)
WO (1) WO2011043827A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
EP3520793B1 (en) 2011-06-06 2023-03-29 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
US9913823B2 (en) * 2011-10-18 2018-03-13 Amorepacific Corporation SIRT 1 activator including syringaresinol
MY194893A (en) * 2014-04-28 2022-12-22 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside
CA2975217C (en) 2015-02-13 2023-08-15 Mars, Incorporated Pet food feeding system
KR20170002846A (ko) 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
GB201522304D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for reducing muscle breakdown
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
EP4039329A4 (en) * 2019-10-04 2023-08-02 Suntory Holdings Limited COMPOSITION FOR SUPPRESSING LOSS OF MUSCLE MASS, PREVENTING LOSS INSIDE, MAINTAINING, RECOVERING OR ENHANCING ITS INSIDE
KR102623198B1 (ko) * 2020-02-26 2024-01-10 한국 한의학 연구원 돌콩 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소의 예방, 개선 또는 치료용 조성물
RU2756154C1 (ru) * 2020-11-13 2021-09-28 Митхат Зульфугар-Оглы Гасанов Способ диагностики саркопении у пациентов с хронической болезнью почек 5д стадии, получающих лечение программным гемодиализом
WO2023140407A1 (ko) * 2022-01-21 2023-07-27 경상국립대학교병원 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166380B (es) 1973-07-09 1975-03-28
US6887499B2 (en) * 2000-05-22 2005-05-03 Enitan A. Bababunmi Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
EP1192943A3 (en) * 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
JP5384777B2 (ja) 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
WO2005007676A2 (en) 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
JP2007519743A (ja) 2004-01-29 2007-07-19 エリクシアー ファーマシューティカルズ， インコーポレイテッド ウイルス障害の処置
CA2559974C (en) * 2004-03-17 2012-08-14 Nestec S.A. Compositions and methods for reducing or preventing obesity
JP2009537582A (ja) 2006-05-24 2009-10-29 ディーエスエム アイピー アセッツ ビー．ブイ． 有機化合物の新しい用途
JP5345534B2 (ja) * 2006-08-24 2013-11-20 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法

Also Published As

Publication number Publication date
EP2485740A1 (en) 2012-08-15
AU2010303872A1 (en) 2012-04-19
IN2012DN02624A (es) 2015-05-22
CA2776950A1 (en) 2011-04-14
JP2013507361A (ja) 2013-03-04
MX2012004118A (es) 2012-05-08
RU2558534C2 (ru) 2015-08-10
WO2011043827A1 (en) 2011-04-14
US20120238515A1 (en) 2012-09-20
JP6122638B2 (ja) 2017-04-26
EP2485740B1 (en) 2018-08-29
CN102573857A (zh) 2012-07-11
EP2485740A4 (en) 2013-04-03
CA2776950C (en) 2023-11-21
RU2012118686A (ru) 2013-11-20
AU2010303872B2 (en) 2016-06-23
BR112012008238A2 (pt) 2017-06-06
US9301941B2 (en) 2016-04-05

Similar Documents

Publication Publication Date Title
ES2688447T3 (es) Métodos para prevenir o tratar la sarcopenia y la atrofia muscular en animales
CY1115203T1 (el) Προφαρμακα οξινου φουμαρικου μεθυλ εστερα, φαρμακευτικες συνθεσεις αυτων και μεθοδοι χρησης
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
EA200800451A1 (ru) Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
CY1117655T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
DE602005019465D1 (de) Bi- und trizyklische substituierte phenyl-methanone als inhibitoren von glycin-i (glyt-1)-transportern zur behandlung der alzheimer-krankheit
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
EA201101085A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
UY32305A (es) AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR BcI2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
AR067505A1 (es) Derivados de pirimidinil-piridazinona
ECSP099525A (es) Inhibidores de mek
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
CL2008003366A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados, inhibidores de proteinas quinasas mek y mapk/erk; proceso de preparacion de los compuestos; composicion farmaceutica que los comprende; conjunto que los comprende; y su uso en la preparacion de medicamentos para el tratamiento de trastornos hiperproliferativos.
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa